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Introduction
More than 25 years into the human immunodeficiency virus (HIV) epidemic, in excess of
two million new infections continue to occur each year, and approximately two million
people died of AIDS-related causes in 2007 alone (UNAIDS 2008). From a scientific and
public health perspective, primary HIV prevention research, as well as research with those
acutely infected and with established infections, should focus predominately on
communities and groups with high HIV incidence. But while research is crucially important
for groups at heightened risk for HIV, the design and conduct of HIV prevention research
with these populations continues to raise considerable ethical challenges, particularly in
social contexts marked by poverty, weak health care infrastructures, inequity, discrimination
and stigma.
The HIV Prevention Trials Network (HPTN) is a global collaborative network that conducts
clinical and behavioral studies on non-vaccine interventions to reduce the transmission of
HIV. In keeping with its mission to carry out HIV prevention research at the highest ethical
standards, the HPTN Ethics Working Group (EWG) issued its Ethics Guidance for Research
in 20031. A number of important developments over the ensuing years prompted the HPTN
to revise its ethics document in 2009. In what follows, we describe the developments that
motivated the drafting of a revised ethics document, the process by which that revision took
place, and some of the key differences between the HPTN ethics document and other
relevant guidance in the field.
1. Relevant scientific, policy and ethical developments in HIV prevention
since 2003
In the past few years, the global struggle against HIV/AIDS has been a tumultuous affair,
marked by striking progress and significant setbacks. On the positive side, global initiatives
have increased patient access to antiretroviral treatment, including treatment to prevent
mother-to-child HIV transmission, particularly in developing countries with high HIV
incidence. ‘Provider-initiated’ HIV testing policies have become more commonplace,
increasing the number of persons who know their HIV status. In HIV prevention research,
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the greatest success story over this time period was male circumcision, as three randomized
controlled trials in Uganda, Kenya and South Africa indicated that circumcision produced a
60% reduction in HIV transmission risk from women to men. On a less positive note, a
number of promising HIV prevention trials of vaccines, microbicides, sexually transmitted
disease (STI) reduction and diaphragms have shown no statistically significant protective
effect. Trials on pre-exposure prophylaxis (PREP) in Cambodia and Cameroon were halted
prematurely after complaints from community groups, accusations from activist
organizations and unfavorable media coverage.
Since 2003, there has also been greater attention in the scientific literature to ethical issues
related to HIV prevention research, such as ethical obligations towards study participants
who become HIV-positive during a trial; involvement of vulnerable groups, particularly
adolescents, intravenous drug users (IDUs) and pregnant women; ethical obligations towards
non-research participants, such as male partners in microbicide trials; ancillary care
responsibilities of researchers towards research participants; responsiveness of research to
local health priorities; and the use of novel approaches to develop, monitor and evaluate
informed consent processes. A number of new or revised ethics and policy documents
relevant to HIV prevention research were also published between 2003 and 2009. These
include the Global Campaign for Microbicides’ Rethinking the Ethical Roadmap for Clinical
Testing of Microbicides (2005); UNAIDS Ethical Considerations in Biomedical HIV
Prevention Trials (2007); UNAIDS Good Participatory Practice Guidelines for Biomedical
HIV Prevention Trials (2007); revisions of the Declaration of Helsinki (2008); the Institute
of Medicine’s Methodological Challenges in HIV Prevention Trials (2008). Finally, the
ethical challenges with the pre-exposure prophylaxis trials in Cameroon and Cambodia were
the subject of two detailed reports2, 3.
The revised HPTN ethics guidance document also partly emerged from empirical activities
conducted by HPTN. Between 2003 and 2009, members of HPTN’s Ethics Working Group
(EWG) conducted research on the ancillary care obligations of research, the collection of
biological specimens4, standards of care within HIV prevention trials5, 6, perceptions of
ethical challenges within the HPTN7, and informed consent8.
2. Developing the ethics guidance
The revision process began with a review of preliminary data from a study of actual ethical
issues encountered within HPTN research. Research by Borasky et. al.7 used phone
interviews to explore ethical challenges and concerns (regarding responsiveness of research
to local needs, post-trial access, standards of care and ancillary care) experienced by those
involved in HPTN research, including investigators, study coordinators, IRB members and
community advisory board (CAB)/community working group (CWG) members at HPTN
research sites in Asia, Africa, South America and the United States. Using these preliminary
data and an extensive literature review in order to generate preliminary ethics guidance
points and issues, a first draft of a revised ethics guidance document was developed. In
November 2008, this draft was circulated to members of the HPTN EWG and other
participants in advance of an intensive 2-day meeting to discuss and revise the document.
Participants in the meeting included members of working groups (CWG and EWG) within
HPTN, representatives of different divisions within NIH (NIHM, NIAID, OAR and NIDA),
representatives from other NIH funded networks working on HIV prevention [HIV Vaccine
Trials Network (HVTN) and Microbicides Trial Network (MTN)], and Family Health
International (FHI) which supports the work of the HPTN. The participants discussed the
selection and content of ethics guidance points, attempting to reach consensus among
participants on their specific formulations. These discussions were themselves framed and
guided by HPTN’s commitment to the fundamental ethical principles of research including
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respect for persons, beneficence and social justice. After formulating each ethics guidance
point, participants attempted to reach consensus on the ethical status of the guidance point
(obligatory or aspirational, described in more detail below) and identify who among the
stakeholders was primarily responsible for its fulfillment. The initial designation of the
ethical status of guidance points proved particularly challenging, as it involves a delicate
balance between making the ethical responsibilities of researchers overly demanding (and
possibly inhibiting valuable research) or not demanding enough (and failing to adequately
meet fundamental ethical principles). A second draft version of the ethics guidance,
emerging from this meeting, was then circulated within the HPTN, including CWG
members at study sites around the world, to gain further feedback, criticism and advice. The
ethics guidance document subsequently underwent three substantial revisions as it was
critically examined by the HPTN; the revision process added new guidance points and
issues, altered the ethical status of some guidance points, and changed some of the
stakeholders responsible for them. A sixth version of the ethics guidance was then
distributed for external review and feedback (via email correspondence or listserves) to a
number of important stakeholders and experts in the ethics of global health research, such as
those involved in Fogarty/NIH research ethics capacity-building initiatives, bioethics centers
worldwide, the Wellcome Trust, and the European and Clinical Trials Partnership (EDCTP).
Comments and criticisms were incorporated into a final version of the new ethics guidance
which was approved by the Executive Committee of the HPTN in May 2009 and posted on
its website9.
3. Approach and goals
The HPTN ethics guidance aims to serve as a useful, practical guide for addressing ethical
challenges in all HPTN research, including behavioral studies and non-clinical, community
based trials. In keeping with this practical orientation, the points in the ethics guidance are to
be integrated into the design, implementation and dissemination of HPTN research. The
primary audience of the ethics guidance, therefore, are those involved within the HPTN or
those directly affected by its activities. However, given that the 2003 HPTN ethics guidance
was regarded as an important contribution to ethical discussions surrounding HIV
prevention research10, 11, the updated guidance aims to be useful for other groups and
agencies conducting similar research, and to a general audience interested in issues related
to HIV prevention and ethics.
4. Key differences with other related guidance
Unlike related guidance documents, which are organized thematically, the HPTN ethics
guidance is structured according to the continuum of research: ethical issues before research
begins, ethical issues during the conduct of research, and ethical issues after data collection
is completed. Within this structure, the document presents and develops 15 ethics guidance
points in detail (see Box 1).
The 15 ethics guidance points overlap to some extent with existing guidance relevant to HIV
prevention research, particularly the UNAIDS Ethical Considerations in Biomedical HIV
Prevention Trials (2007). Unlike that document, however, the 2009 HPTN ethics guidance
specifies the ethical status of each guidance point, because it emerged during discussions
about the prior HPTN ethics guidance that researchers wanted to know if specific guidance
points constituted ethical requirements or recommendations. In the updated guidance, some
guidance points are regarded as ethical obligations, i.e. the actions prescribed by the
guidance point normally ought to be followed, and exceptions require a strong ethical
justification. Other guidance points are regarded as ethical aspirations, i.e. it would be
praiseworthy or commendable to follow the course of action prescribed by the guidance
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point, though it is not ethically required. Each guidance point also states who among the
stakeholders -- sponsors, principal investigators, protocol teams, Community Working
Group, etc. -- is responsible and accountable for ensuring that each guidance point is taken
into account. The aim of stipulating the ethical status of each guidance point, as well as
identifying those responsible for their fulfillment, is to render the HPTN ethics guidance
more directive and user-friendly. In addition, short case studies or vignettes based on actual
HPTN research experiences are used throughout the ethics guidance document to illuminate
selected guidance points.
In what follows, we specify some of the more substantive differences between the HPTN
ethics guidance and other regulations or guidance relevant to HIV prevention research. The
positions of other relevant guidance documents on some key ethical issues are also displayed
in Table 1.
Standard of prevention
In the HPTN ethics guidance, ‘standard of prevention’ is explicitly distinguished from the
more commonly-used notion of ‘standard of care’. Standard of prevention refers to the
package of HIV prevention products or services that will be offered to those that participate
in HPTN research. While it is important, on scientific grounds, for research participants to
be at risk of exposure to HIV, there is a wide ethical consensus that they must be provided
with effective means to protect themselves from acquiring the virus. Ethical discussions
therefore revolve around the precise content of the ‘prevention package,’ beyond a minimum
of HIV voluntary testing and counseling, HIV and STI risk reduction, and provision of male
and female condoms.
On this point, the UNAIDS Ethical considerations in biomedical HIV prevention trials
(2007) is unambiguous: “Researchers, research staff, and trial sponsors should ensure, as an
integral component of the research protocol, that appropriate counseling and access to all
state of the art HIV risk reduction methods are provided to participants throughout the
duration of the biomedical HIV prevention trial” (Guidance Point 13). This echoes the
Declaration of Helsinki (2008), which states: “The benefits, risks, burdens and effectiveness
of a new method should be tested against those of the best current proven intervention”
(Paragraph 32). The new HPTN ethics guidance takes a less categorical and more pragmatic
position. It defines the necessary conditions for an acceptable prevention package within
HIV prevention research as those services (a) known to be effective in preventing HIV
transmission, (b) practically achievable as a standard in the local setting and (c) reasonably
accessible by those screened or enrolled in HIV prevention. These conditions are partly
motivated by concerns about research studies creating inequities by providing participants
with comprehensive prevention services unavailable to local communities and unfeasible to
integrate into local health systems. In addition, the HPTN guidance acknowledges that some
prevention services (like male circumcision) may be culturally inappropriate for some
communities, and the provision of others (such as needle exchange) may be illegal and place
participants at added risk. Finally, insisting on ‘state of the art’ prevention in every context
may compromise the real-world significance of the data, and the production of irrelevant
research is both a scientific and ethical concern. Experiences of HPTN researchers working
in the field, as well as members of IRBs/research ethics committees, representatives of
CABs and Community Working Groups reveal a tension between the ideal to improve local
standards of care and treatment and practical obstacles researchers face when pursuing this
ideal. In general, the HPTN ethics guidance is grounded in pragmatism which recognizes
that HIV prevention research must be conducted according to the highest ethical standards,
but at the same time, lofty ethical aspirations will not have a meaningful social impact if
they cannot be applied in the concrete research settings and the political, social, economic,
cultural and regulatory contexts in which they are embedded.
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Provision of successful research interventions
The Declaration of Helsinki (2008) states that at the conclusion of a research study, research
participants are entitled to share any benefits resulting from the research, including
interventions identified as beneficial (Paragraph 33). The HPTN ethics guidance reflects
concerns (also expressed by CIOMS and Nuffield Council on Bioethics) that immediate
provision of successful research interventions is not a straightforward matter. Successful
drug interventions may need to undergo lengthy regulatory and production scale-up before
they reach individual research participants; the overall benefits of a new effective
intervention may not be clearly superior to established methods. The HPTN ethics guidance
therefore identifies some key questions to be answered regarding ‘post-trial access’: who
will be financially and logistically responsible for providing the intervention, who will gain
access to the intervention (participants, communities or others) and for how long access will
be provided. Unlike the Nuffield Council of Bioethics (2002), the HPTN ethics guidance
stops short of requiring researchers to develop a ‘post-study access plan’ and integrate it in
their study protocols before their research begins. Instead, it requires researchers to start
planning for access to successful interventions as early as possible, to modify plans as
research unfolds, and to develop an explicit post-study access plan if a beneficial
intervention is identified. The guidance emphasizes that participants should be regularly
informed about developments in regard to post-study access, and ongoing stakeholder and
community consultation is crucial to appropriate sharing of benefits after research is over.
As the research by Borasky et. al. reveals, however, developing post-access plans have often
not been experienced as a major concern for HIV prevention researchers, for the unfortunate
reason that very few studies have yielded effective interventions7.
Continuing care for research participants
What obligations do HIV prevention researchers have when a research participant, despite
being provided with the ‘prevention package’, becomes HIV positive during the course of
the study? According to UNAIDS (2007a), “Participants who acquire HIV infection during
the conduct of a biomedical HIV prevention trial should be provided access to treatment
regimens from among those internationally recognized as optimal” (Guidance point 14).
Some involved in HIV research and ethics argue that with the increase in access to
antiretroviral treatment and care services around the world, there is a ‘consensus’ that those
who seroconvert during a trial should be guaranteed access to care and treatment.12 Others
claim that, on closer inspection, this obligation has no rational or ethical basis, because the
provision of treatment cannot be justified by a principle of reciprocity or claims of research-
related injury.13
The HPTN ethics guidance takes a moderate position within this debate. While access to
antiretroviral treatment on the part of seroconverters should be the goal, care must be taken
not to create or worsen inequities in access to treatment. In addition, those who become HIV
positive may not require antiretroviral treatment for a number of years, by which time
antiretroviral drugs may (and should) already form part of local HIV care and treatment
services. While investigators should ensure that study participants do not suffer
discontinuity of care and treatment, research projects cannot reasonably be expected to act
as substitutes for local health systems. If, in the worst case scenario, it is highly unlikely that
local health services will be able (or willing) to assume care and treatment for those who
seroconvert during a HIV prevention study in the foreseeable future, researchers may wish
to consider alternative study sites. On the other hand, the HPTN ethics guidance
acknowledges that moving HIV prevention studies to better resourced settings may itself
perpetuate or exacerbate existing inequities, and therefore takes the position that research
may be permissible in locations where treatment and care for those who seroconvert is not
yet guaranteed, as long as host governments and communities are committed to the research
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and if the study’s capacity-building plan includes improvement of local HIV/AIDS services
and care.
Standards of care and treatment
Standards of prevention refer to what research participants may or may not receive to lower
their risk of HIV infection. Standards of care and treatment refer to the package of medical
and health-related services research participants can expect to receive during the course of a
study. The HPTN ethics guidance differs from other guidelines in clearly differentiating
domains of care to be considered and by its attention to the impact that provision of care and
treatment to research participants may have on local health systems. The different domains
of care and treatment include: care and treatment for those screened but failing to meet study
inclusion criteria due to a pre-existing medical condition; care and treatment provided for
research-related reasons; care and treatment provided to participants for medically
significant findings occurring during study participation (‘ancillary care’), and care,
treatment or monetary compensation for research-related injuries. The guidance stresses that
research teams must initially make a thorough investigation of standards of care and
treatment at study sites, provide at the very least equivalent services if the standards are
adequate, and seek to enhance local standards if they are unacceptably low.
The HPTN ethics guidance is one of the few to include discussion of the ancillary care
responsibilities of researchers, and to confront the thorny question of compensation for
research-related harm. In regard to the former, the guidance stresses the need to know the
prevailing health conditions at research sites to at least anticipate some of the ancillary care
needs research participants are likely to experience. This knowledge, together with the
results of ongoing dialogue with local communities, should be incorporated into research
protocols and periodically reviewed in the light of new data. In regard to compensation for
harm, the guidance points out that while the National Institutes of Health (NIH) does not
provide medical care or financial compensation, compensation for injury can be handled at
the site level by arrangements with institutions collaborating in the research, and in some
cases NIH funds can be used to purchase insurance coverage to cover research-related
injuries. The ethics guidance stresses the need for clear communication in what can be a
highly sensitive area: if compensation will not be offered, this should be stated
unambiguously in the consent process. If compensation will be offered, the nature of the
compensation should be explicitly described incorporating considerations from relevant
legal codes and spelling out clearly what constitutes negligent and non-negligent harm,
whether medical treatment or financial compensation will be involved, and the process by
which harms will be determined to be research-related and compensated.
Engaging communities
Community engagement is a motif running through virtually all guidance points of the
HPTN ethics document. The importance of community engagement is regarded as both
intrinsic and instrumental, i.e. the involvement of communities in research expresses respect
for local communities and enhances the ability to conduct and complete HIV prevention
research. The HPTN ethics guidance differs from other related documents, as some have
noted14, by providing a working definition of ‘community’, as the group of people who will
participate in, or are likely to be affected by or have an influence on the conduct of research.
While community engagement is a feature in other ethics documents, the HPTN guidance
goes into greater detail on its processes and challenges on the basis of HPTN’s long
experience with participatory community research. The guidance stresses the need to
meaningfully involve communities at the earliest stages of the research process,
acknowledges that both community members and researchers need to explore each other’s
perspectives and concerns through ‘joint literacy’, describes the importance of identifying
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appropriate community representatives, explains how the boundaries of community may be
expanded by the addition of new stakeholders, and suggests ways of improving
communication between researchers, community representatives and members of
community advisory boards.
4. Future challenges
The most immediate challenge is to fully operationalize the guidance points of the updated
ethics guidance within the day-to-day research practices of the HPTN. Interviews with
HPTN stakeholders suggest that the guidance points from the previous ethics document
were not always routinely and explicitly taken into account when designing, conducting and
disseminating HPTN research7. To improve implementation in the future, mechanisms that
engage relevant guidance points -- such as ethics checklists researchers must complete in
their protocols -- will be developed for each phase along the research continuum.
Ethics guidance such as this are faced with two major challenges: remaining relevant over
time and adding significant value to the ethics guidance that already exists. Remaining
relevant for the rapidly evolving field of HIV prevention research is especially challenging.
Even during the period that the updated HPTN ethics guidance was being developed, HIV
prevention research trends appeared which may pose novel ethical questions. For example,
current HIV prevention research is being conducted into the effectiveness of a ‘test and
treat’ approach, i.e. aggressively testing for HIV and providing anti-retroviral treatment to
HIV-positive persons regardless of their viral load or CD4 count. This type of research
raises ethical issues around behavioral disinhibition, individual patient benefit and drug
resistance15. While the 2009 HPTN ethics guidance does not directly address this particular
approach, it does provide some analytic and conceptual tools which may be useful for this
and other emerging ethical problems. In regard to the need for (yet another) ethics guidance,
it should be noted that existing ethics guidance have some serious shortcomings for those
engaged in HIV prevention research. The usefulness of some current guidance may be
limited, either because they are pitched at too high a level of generality or because they are
not sufficiently grounded in the realities of collaborative research involving vulnerable
populations. In addition, research ethics guidance tends to focus on ethical issues arising
from clinical research with patient populations, rather than the testing of prevention methods
(both biomedical and behavioral) with non-patient, at-risk groups. The updated HPTN ethics
guidance aims to guide HPTN’s mission of conducting HIV prevention research at the
highest ethical standards while helping to fill a gap in this important area of research ethics.
Acknowledgments
The members of the HPTN Ethics Working Group at the time the Ethics Guidance Document was revised were:
Quarraisha Abdool-Karim, Missie Allen, Mark Barnes, Solomon Benatar, David Borasky, Marge Chigwanda. Amy
Corneli, Deborah Donnell, Vanessa Elharrar, Janet Frohlich, Sukanya Linpisarn, Bernard Lo, Alex London, Derrick
Mapp, Kathleen MacQueen, Joseph Mfutso-Bengo, Vasantha Muthuswamy, Nirupama Sista, Ronald Strauss,
Jeremy Sugarman, Steven Wakefield, Ruotao Wang, and Cynthia Woodsong. The authors also gratefully
acknowledge the valuable input of Liza Dawson (DAIDS), Renee Holt (HVTN), and Lisa Noguchi (MTN) in the
drafting of the HPTN ethics guidance, and Bonnie Dye (FHI) for invaluable technical assistance.
Funding: Work on this document was supported by Grant Number U01 AI068619 from the National Institute of
Allergy And Infectious Diseases (NIAID), with additional support from the National Institute on Drug Abuse
(NIDA) and National Institute of Mental Health (NIMH). The content is solely the responsibility of the authors and
does not necessarily represent the official views of the NIAID, NIDA, NIMH, or the National Institutes of Health.
References
1. MacQueen KM, Karim QA, Sugarman J. Ethics guidance for HIV prevention trials. BMJ. 2003;
327(7410):340. [PubMed: 12907494]
Rennie and Sugarman Page 7













2. Microbicides GCf. A case study and lessons for future trials from the 2004 Tenofovir trial in
Cambodia. 2009. Preventing prevention trial failures.
3. Microbicides GCf. Research Rashomon: lessons for the Cameroon pre-exposure prophylaxis trial
site. 2009.
4. MacQueen KM, Alleman P. International perspectives on the collection, storage, and testing of
human biospecimens in HIV research. Irb. 2008; 30(4):9–14. [PubMed: 18767319]
5. MacQueen KM, Namey E, Chilongozi DA, Mtweve SP, Mlingo M, Morar N, et al. Community
perspectives on care options for HIV prevention trial participants. AIDS Care. 2007; 19(4):554–60.
[PubMed: 17453597]
6. Macqueen KM, Johnson L, Alleman P, Akumatey B, Lawoyin T, Nyiama T. Pregnancy prevention
practices among women with multiple partners in an HIV prevention trial. J Acquir Immune Defic
Syndr. 2007; 46(1):32–8. [PubMed: 17667340]
7. Borasky D, Amsterdam A, Sugarman J, McQueen K, Corneli A. Ethical challenges in HIV
prevention research: perceptions within the HIV Prevention Trials Network (HPTN). Manuscript in
preparation. 2010
8. Woodsong C, Macqueen K, Namey E, Sahay S, Morar N, Mlingo M, et al. Women’s Autonomy and
Informed Consent in Microbicides Clinical Trials. J Empir Res Hum Res Ethics. 2006; 1(3):11–26.
[PubMed: 19385819]
9. HIV Prevention Trials Network. Research ethics. Available at:
http://www.hptn.org/hptnresearchethics.htm
10. Muthuswamy V. Ethical issues in HIV/AIDS research. Indian J Med Res. 2005; 121(4):601–10.
[PubMed: 15817966]
11. Global Campaign for Microbicides. Rethinking the ethical roadmap for clinical testing of
microbicides: report on an international consultation. 2005.
12. Macklin R. Standard of care: an evolution in ethical thinking. Lancet. 2008; 372:284–285.
[PubMed: 18663793]
13. Weijer C, LeBlanc G. The balm of Gilead: is the provision of treatment to those who seroconvert
in HIV prevention trials a matter of moral obligation or moral negotiation? Journal of Law,
Medicine and Ethics. 2006; 34(4):793–808.
14. Collins, C. Prepared for UNAIDS as a background paper for three regional workshops and an
international consultation on ‘Creating effective partnerships for HIV prevention trials in
developing countries’. 2005. Gaps and inconsistencies in ethical guidance for HIV prevention
research.
15. McEreny, R. Test and treat on trial: European AIDS Treatment Group. 2009.
Rennie and Sugarman Page 8














HPTN ethics guidance points
Before research
Ensuring high-quality scientific and ethical research
Setting research objectives and priorities
Engaging communities
Building local capacity and partnerships
Ethical issues in study design
Consent, assent, permission and re-consent
Addressing vulnerabilities
Ethical review of research
During research
Standard of prevention
Standards of care and treatment
Independent data safety and monitoring
After research
Disseminating research results
Sustaining capacity-building and infrastructure into the future
Continuing care for research participants
Provision of successful research interventions
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Challenges to protecting vulnerable populations in research
Injection drug users (IDUs) are stigmatized to such a great extent that it is very difficult
to provide traditional research protections for IDUs who enroll in HIV prevention
research. IDUs are often regarded by local governments, local police authorities and
many community members as common criminals, and research involving them tends to
be discouraged. When research does occur, the government closely monitors who the
IDUs are and the local police, who have all the names of participants, may watch them
coming in and out of the clinic. In this political and social context, the idea of providing
true confidentiality protections for these research participants does not apply, so
researchers are forced to look to other risk-reduction approaches for this population. This
can involve educating police about proposed research in order to minimize risk to
participants.
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